OCUL · Ocular Therapeutix, Inc · Documents

Apr 29

Proxy statement DEF 14A Meeting Jun 12, 2024

Proxy statement

Apr 29

Annual report to holders ARS

Annual report to holders

Apr 19

Proxy statement PRE 14A Meeting Jun 12, 2024

Proxy statement

Apr 18

Current report 8-K Events of Apr 14

Director or officer change, or executive pay

Mar 29

Current report 8-K Events of Mar 28

Other events

Mar 25

Registration statement S-3ASR

Registration statement

Mar 11

Current report 8-K

Financial results

Mar 11

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $58.44M ▲ 13.5% Net loss $80.74M Diluted EPS -$1.02

Feb 22

Current report 8-K Events of Feb 20

Entered into a material agreement, Financial results, Unregistered sale of equity, Director or officer change, or executive pay, Other events

Jan 25

Current report 8-K

Other events

Dec 14

Current report 8-K Events of Dec 13

Entered into a material agreement, Other events

Nov 7

Earnings call

Q3 2023 earnings call

Nov 7

Current report 8-K

Financial results

Nov 7

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $15.08M ▲ 26.0% Net loss $516K Diluted EPS -$0.25

Nov 7

Registration statement S-3

Registration statement

Oct 4

Current report 8-K

Regulation FD disclosure

Oct 3

Current report 8-K

Other events

Sep 13

Current report 8-K Events of Sep 12

Other events

Aug 7

Earnings call

Q2 2023 earnings call

Aug 7

Current report 8-K

Financial results

Aug 7

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $15.19M ▲ 23.8% Net loss $20.68M Diluted EPS -$0.26

Jul 12

Current report 8-K Events of Jul 10

Director or officer change, or executive pay

Jul 7

Current report 8-K Events of Jun 30

Entered into a material agreement

Jun 16

Current report 8-K Events of Jun 14

Director or officer change, or executive pay, Shareholder vote results

Jun 12

Current report 8-K Events of Jun 10

Other events

May 8

Earnings call

Q1 2023 earnings call

May 8

Current report 8-K

Financial results

May 8

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $13.37M ▲ 1.4% Net loss $30.32M Diluted EPS -$0.39

May 1

Proxy statement DEF 14A Meeting Jun 14, 2023

Proxy statement

May 1

Annual report to holders ARS

Annual report to holders

May 1

Proxy statement DEFA14A

Proxy statement

Apr 6

Current report 8-K Events of Mar 31

Entered into a material agreement

Mar 6

Current report 8-K

Financial results

Mar 6

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $51.49M ▲ 18.3% Net loss $71.04M Diluted EPS -$0.97

Jan 6

Earnings call

Q4 2022 earnings call

Jan 6

Current report 8-K

Financial results

Nov 7

Earnings call

Q3 2022 earnings call

Nov 7

Current report 8-K

Financial results

Nov 7

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $11.97M ▼ 1.5% Net loss $24.19M Diluted EPS -$0.31

Sep 30

Current report 8-K Events of Sep 29

Regulation FD disclosure

Aug 8

Earnings call

Q2 2022 earnings call

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $12.27M ▲ 4.7% Net loss $18.77M Diluted EPS -$0.25

Jun 17

Current report 8-K Events of Jun 16

Director or officer change, or executive pay, Shareholder vote results

Jun 8

Current report 8-K Events of Jun 3

Director or officer change, or executive pay

May 9

Earnings call

Q1 2022 earnings call

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $13.19M ▲ 79.6% Net loss $12.54M Diluted EPS -$0.22

May 2

Proxy statement DEF 14A Meeting Jun 16, 2022

Proxy statement

May 2

Proxy statement DEFA14A

Proxy statement